68 Ga-PSMA-11 in Staging of Unfavorable Intermediate- and High-Risk Prostate Cancer Reduces Indication for Noncurative Prostatectomy: A Prospective, Multicenter, IAEA Study
Journal of Nuclear Medicine · 2026
DOI: 10.2967/jnumed.125.270537 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Nuclear Medicine, 2026. Verfasst von Juliano J Cerci und 14 weiteren Autor:innen. Beteiligte Einrichtung: Quanta Diagnostico e Terapia, Curitiba, Brazil; cercijuliano@hotmail.com. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Positron Emission Tomography Computed Tomography, Prostatectomy, Edetic Acid. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Accurate staging of unfavorable intermediate- or high-risk prostate cancer (PCa) is essential for treatment decisions. Conventional imaging often fails to detect lymph node, bone, and visceral metastases, and for this purpose 68Ga-prostate-specific membrane antigen (PSMA)-11 PET/CT is clinically used. This prospective, multicenter, International Atomic Energy Agency-supported trial evaluated the accuracy of 68Ga-PSMA-11 PET/CT for initial staging compared with MRI and histopathology and the impact of 68Ga-PSMA-11 PET/CT on determining surgical eligibility.
Methods
In a prospective, international study supported by the International Atomic Energy Agency, 775 patients with high-risk or unfavorable intermediate-risk PCa from 12 centers across 11 countries-including low-, middle-, and high-income settings, scheduled for radical prostatectomy based on conventional imaging (including bone scanning and pelvic MRI) underwent 68Ga-PSMA-11 PET/CT before treatment. PET and MRI findings were compared with radical prostatectomy histopathology, and the impact of PET on radical prostatectomy was assessed.
Results
68Ga-PSMA-11 PET/CT detected metastatic disease (M1) in 20.4% of cases, altering management and preventing prostatectomy in 24.0%. The accuracy for seminal vesicle invasion was 90.1% for 68Ga-PSMA-11 PET/CT versus 57.3% for MRI, and for lymph node metastases it was 91.1% for 68Ga-PSMA-11 PET/CT versus 69.7% for MRI. In 13.1% of patients (78/593), there were discordant results between 68Ga-PSMA-11 PET/CT and histopathology. 68Ga-PSMA-11 PET/CT had false-negative lymph node findings in 8.6% of cases, with the most clinically significant being 4.5% of patients incorrectly staged as N0. False-positive lymph node findings at 68Ga-PSMA-11 PET/CT occurred in 4.5% of patients.
Conclusion
68Ga-PSMA-11 PET/CT significantly improves staging accuracy, reducing the indication for prostatectomy and impacting treatment decisions. These findings, from a broad international cohort including low-, middle-, and high-income countries, support the global adoption of 68Ga-PSMA-11 PET/CT into standard staging protocols for high-risk PCa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Quanta Diagnostico e Terapia, Curitiba, Brazil; cercijuliano@hotmail.com.
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- Division of Human Health, International Atomic Energy Agency, Vienna, Austria.
- All India Institute of Medical Sciences, New Delhi, India.
- Nuclear Medicine Department, Medical University of Warsaw, Warsaw, Poland.
- King Hussein Cancer Center, Amman, Jordan.
Zitieren
APA
Cerci, J. J., Fanti, S., Lobato, E. E., Kumar, R., Kunikowska, J., Al-Ibraheem, A., Nasir, M., Redondo Moneda, F., Garcia, O., Haidar, M., Novruzov, F., Kucuk, O., Elboga, U., de Almeida Luz, M., & Paez, D. (2026). 68 Ga-PSMA-11 in Staging of Unfavorable Intermediate- and High-Risk Prostate Cancer Reduces Indication for Noncurative Prostatectomy: A Prospective, Multicenter, IAEA Study. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.125.270537
Vancouver
Cerci JJ, Fanti S, Lobato EE, Kumar R, Kunikowska J, Al-Ibraheem A, et al. 68 Ga-PSMA-11 in Staging of Unfavorable Intermediate- and High-Risk Prostate Cancer Reduces Indication for Noncurative Prostatectomy: A Prospective, Multicenter, IAEA Study. Journal of Nuclear Medicine. 2026. doi:10.2967/jnumed.125.270537
BibTeX
@article{Cerci2026,
author = {Cerci, Juliano J and Fanti, Stefano and Lobato, Enrique E and Kumar, Rakesh and Kunikowska, Jolanta and Al-Ibraheem, Akram and Nasir, Maisarah and Redondo Moneda, Francisca and Garcia, Osvaldo and Haidar, Mohamad and Novruzov, Fuad and Kucuk, Ozlem and Elboga, Umut and de Almeida Luz, Murilo and Paez, Diana},
title = {68 Ga-PSMA-11 in Staging of Unfavorable Intermediate- and High-Risk Prostate Cancer Reduces Indication for Noncurative Prostatectomy: A Prospective, Multicenter, IAEA Study},
journal = {Journal of Nuclear Medicine},
year = {2026},
doi = {10.2967/jnumed.125.270537}
}
EUVIMED